4.5 Article

Pretreatment Cardiometabolic Status in Youth With Early-Onset Psychosis: Baseline Results From the TEA Trial

Journal

JOURNAL OF CLINICAL PSYCHIATRY
Volume 78, Issue 8, Pages E1035-+

Publisher

PHYSICIANS POSTGRADUATE PRESS
DOI: 10.4088/JCP.15m10479

Keywords

-

Funding

  1. Tolerability and Efficacy of Antipsychotics (TEA)
  2. National Research Council for Health and Disease
  3. Danish Association for Mental Health
  4. Mental Health Centre for Child and Adolescent Psychiatry Bispebjerg
  5. Capital Region Psychiatric Research Foundation
  6. A.P. Moller Foundation
  7. Tryg Fonden
  8. Capital Region Research Foundation
  9. Region of Southern Denmark Research Foundation
  10. Psychiatry Foundation
  11. Knud og Dagny Andresens Foundation
  12. Psychiatric Research Foundation
  13. Dr Sofus Carl Emil Friis and Hustru Olga Friis Scholarship
  14. Psychiatric Research Foundation, Region Zealand
  15. Tomrerhandler Johannes Fogs Foundation
  16. Brdr Hartmanns Foundation
  17. Aase and Ejnar Danielsens Foundation
  18. Jacob Madsen and wife Olga Madsen's Foundation
  19. C.C. Klestrup and wife Scholarship
  20. Tomrermester Jorgen Holm and wife Elisas Scholarship
  21. Lundbeck Foundation [R155-2013-16337] Funding Source: researchfish

Ask authors/readers for more resources

Objective: To describe pretreatment cardiometabolic constitution in children and adolescents with first-episode psychosis (FEP). Methods: Baseline cardiometabolic assessment was performed in youths aged 12-17 years with FEP entering the Tolerability and Efficacy of Antipsychotics (TEA) trial and matched healthy controls. Patients were included between June 10, 2010, and January 29, 2014. ICD-10 was used as the diagnostic classification system. Cardiometabolic risk markers were compared between patients versus controls and antipsychotic-naive versus antipsychotic-exposed patients. Results: Comparing 113 youths with FEP (age +/- SD = 15.74 +/- 1.36 years, males = 30.1%, schizophrenia-spectrum disorders = 92.9%, antipsychoticnaive: n = 57) to 60 controls, patients had higher waist circumference (WC) z scores (1.13 +/- 1.65 vs 0.42 +/- 1.27, P = .018), cholesterol (4.10 +/- 0.71 vs 3.79 +/- 0.49 mmol/L, P = .014), low-density lipoproteins (2.37 +/- 0.56 vs 2.13 +/- 0.51, P = .012), and non-high-density lipoproteins (2.58 +/- 1.60 vs 2.52 +/- 0.52, P = .018). More patients than controls (42.9% vs 20.3%, P = .019) and antipsychotic-naive than antipsychotic-exposed (51.9% vs 34.0%, P = .023) had a WC >90th percentile. Hypercholesterolemia (34.0% vs 12.5%, P = .015) was more frequent in patients, while decreased high-density lipoprotein cholesterol was more frequent in controls (32.5% vs 19.0%, P = .032). Family history of type 2 diabetes mellitus was associated with increased body mass index (BMI) z score (P < .001), WC z score (P = .001), insulin (P = .038), and homeostatic model assessment of insulin resistance (HOMA-IR; P = .025). Dyslipidemia was associated with significantly increased insulin (P = .041), HOMA-IR (P = .032), and low-density lipoprotein cholesterol (P = .041). Previous antipsychotic exposure was not associated with increased cardiometabolic risk. Early age at onset predicted increased BMI and WC z scores, while diagnosis of schizophrenia and higher Clinical Global Impression-Severity score were associated with increased blood lipids. Conclusions: Youths with FEP had significantly greater WC and lipid abnormalities than matched controls, regardless of antipsychotic exposure. In youths with FEP, elevated metabolic risk predates antipsychotic exposure.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available